Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

Trial details

Who runs it

Shanghai Zhongshan Hospital

Trial code

NCT07663253

Record updated

23 June 2026

Original description

Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in China.Read full original descriptionShow less

A Single-Arm, Multicenter, Prospective, Observational Clinical Study on the Efficacy and Safety of Isatuximab Combined With Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Regimen in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI-NDMM) Patients

Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in China.

And Secondary Objectives is， To assess the MRD negativity rate in Chinese TI-NDMM patients treated with Isa-VRd To assess the safety and tolerability of Isa-VRd in Chinese TI-NDMM patients

Participants will:

Receive Isatuximab 10 mg/kg iv

* Cycle 1: Every weeks on Days 1, 8, 15, and 22 * Cycles 2-8: Every 2 weeks on Days 1 and 15 Receive Bortezomib subcutaneous injection 1.3 mg/m² * Cycles 1-8: Days 1, 8, and 15 of each cycle Receive Lenalidomide oral 25 mg/day * Cycles 1-8: Days 1-21 at 25 mg/day (10 mg/day for patients with creatinine clearance [CrCl] ≥30 and <60 mL/min) Receive Dexamethasone oral 20 mg * Cycles 1-8: Days 1, 8, 15, and 22 of each cycle Following Cycle 8, the investigator may assess and adjust the treatment regimen During the induction phase, efficacy assessment is recommended at each treatment cycle. Patients who achieve ≥CR at the end of induction are recommended to undergo the first MRD monitoring assessment.

During the maintenance phase, efficacy assessment is recommended at least every 3 cycles. Patients are recommended to undergo MRD status monitoring (≥CR) every 6 months (i.e., at months 14, 20, and 26) for MRD assessment.

During the follow-up period, MRD status monitoring (≥CR) is recommended every 12 months to observe the depth of response.

Inclusion: Age ≥18 years; Newly diagnosed transplant-ineligible multiple myeloma patients as assessed by investigator, specifically referring to CSCO guidelines; Must meet corresponding laboratory test results (refer to restrictions in package inserts of combination drugs):; Absolute neutrophil count (ANC) ≥1.0×10⁹/L; Platelet count ≥50×10⁹/L; Calculated creatinine clearance ≥30 mL/min (using Cockcroft-Gault formula); Total bilirubin ≤3× upper limit of normal (ULN); TI-NDMM patients intended for Isa-VRd regimen treatment as determined by investigator judgment, independent of study objectives Signed informed consent form (by patient or their legal representative).

Exclusion: Patients who, at the physician's discretion, are unable to tolerate any drug in the combination regimen; Patients with known severe hypersensitivity reactions to Isatuximab or any other excipients; Currently uncontrolled cardiovascular disease, including:; Uncontrolled hypertension; Uncontrolled arrhythmia; Uncontrollable congestive heart failure; Unstable angina; Active infectious disease, known human immunodeficiency virus (HIV) positivity, active hepatitis B or hepatitis C; Patients currently participating in other interventional clinical studies; Severe bacteremia at the time of administration; Patients with peripheral neuropathy ≥Grade 2; Patients who are currently pregnant.

ClinicalTrials.gov NCT07663253